Clinical Challenges in Pulmonary Hypertension

D'Alonzo, 1991, Survival in patients with primary pulmonary hypertension: results from a national prospective registry, Ann Intern Med, 115, 343, 10.7326/0003-4819-115-5-343 Sitbon, 2002, Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival, J Am Coll Cardiol, 40, 780, 10.1016/S0735-1097(02)02012-0 Farber, 2004, Mechanisms of disease: pulmonary arterial hypertension, N Engl J Med, 351, 1655, 10.1056/NEJMra035488 Humbert, 2004, Treatment of pulmonary arterial hypertension, N Engl J Med, 351, 1425, 10.1056/NEJMra040291 Mc Laughlin, 2002, Survival in primary pulmonary hypertension: the impact of epoprostenol therapy, Circulation, 106, 1477, 10.1161/01.CIR.0000029100.82385.58 Mc Goon, 2004, Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines, Chest, 126(suppl), 14S, 10.1378/chest.126.1_suppl.14S Humbert, 2004, ItinerAIR-HTAP: a French national prospective registry og pulmonary arterial hypertension [abstract], Am J Respir Crit Care Med, 169, A169 Grunig, 2000, Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene, Circulation, 102, 1145, 10.1161/01.CIR.102.10.1145 Newman, 2004, Genetic basis of pulmonary arterial hypertension: Current understanding and future directions, J Am Coll Cardiol, 43, S33, 10.1016/j.jacc.2004.02.028 Simonneau, 2004, Clinical classification of pulmonary hypertension, J Am Coll Cardiol, 43, 5S, 10.1016/j.jacc.2004.02.037 Doyle, 2004, Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines, Chest, 126(suppl), 63S, 10.1378/chest.126.1_suppl.63S Filipek, 2004, Multidetector pulmonary CT angiography: advances in the evaluation of pulmonary arterial diseases, Semin Ultrasound CT MR, 25, 83, 10.1016/j.sult.2003.12.003 Mandel, 2000, Pulmonary veno-occlusive disease, Am J Respir Crit Care Med, 162, 1964, 10.1164/ajrccm.162.5.9912045 Humbert, 1998, Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis, Am J Respir Crit Care Med, 157, 1681, 10.1164/ajrccm.157.5.9708065 Nicod, 1989, Primary pulmonary hypertension: the risk and benefit of lung biopsy, Circulation, 80, 1486, 10.1161/01.CIR.80.5.1486 Resten, 2004, Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease, AJR Am J Roentgenol, 183, 65, 10.2214/ajr.183.1.1830065 Rabiller, 2003, Bronchoalveolar lavage as a diagnostic tool in pulmonary hypertension: occult alveolar hemorrhage is a common feature of pulmonary veno-occlusive disease [abstract], Am J Respir Crit Care Med, 167, A276 Barbera, 2003, Pulmonary hypertension in chronic obstructive pulmonary disease, Eur Respir J, 21, 892, 10.1183/09031936.03.00115402 Eddahibi, 2003, Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease, Circulation, 108, 1839, 10.1161/01.CIR.0000091409.53101.E8 Roberts, 2004, BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease, Eur Respir J, 24, 371, 10.1183/09031936.04.00018604 Humbert, 2002, BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives, Eur Respir J, 20, 518, 10.1183/09031936.02.01762002 Mc Laughlin, 2004, Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines, Chest, 126(suppl), 78S, 10.1378/chest.126.1_suppl.78S Badesch, 2004, Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines, Chest, 126(suppl), 35S, 10.1378/chest.126.1_suppl.35S Suleman, 2004, Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension, Chest, 126, 808, 10.1378/chest.126.3.808 Sitbon, 2004, Transition from intravenous epoprostenol to oral bosentan in pulmonary arterial hypertension [abstract], Am J Respir Crit Care Med, 169, A176 Castelain, 2002, Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension, Am J Respir Crit Care Med, 165, 338, 10.1164/ajrccm.165.3.2106033 Enright, 1998, Reference equations for the six-minute walk in healthy adults, Am J Respir Crit Care Med, 158, 1384, 10.1164/ajrccm.158.5.9710086 Frost, 2004, 6MW as an efficacy endpoint in PAH trials: demonstration of a ceiling effect [abstract], Am J Respir Crit Care Med, 169, A176 Sitbon, 2005, Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension, Circulation, 111, 3105, 10.1161/CIRCULATIONAHA.104.488486 Sastry, 2004, Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study, J Am Coll Cardiol, 43, 1149, 10.1016/j.jacc.2003.10.056 Mc Laughlin, 2005, Survival with first-line bosentan in patients with primary pulmonary hypertension, Eur Respir J, 25, 244, 10.1183/09031936.05.00054804 Hoeper, 2000, Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue, N Engl J Med, 342, 1866, 10.1056/NEJM200006223422503 Sitbon, 2003, Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study, Chest, 124, 247, 10.1378/chest.124.1.247 Langleben, 2004, Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study, Chest, 126, 1377, 10.1378/chest.126.4.1377 Barst, 2003, Beraprost therapy for pulmonary arterial hypertension, J Am Coll Cardiol, 41, 2119, 10.1016/S0735-1097(03)00463-7 Olschewski, 2002, Inhaled iloprost for severe pulmonary hypertension, N Engl J Med, 347, 322, 10.1056/NEJMoa020204 Nagaya, 1999, Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension, J Am Coll Cardiol, 34, 1188, 10.1016/S0735-1097(99)00312-5 Barst, 1996, A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group, N Engl J Med, 334, 296, 10.1056/NEJM199602013340504 Ghofrani, 2003, Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension, J Am Coll Cardiol, 42, 158, 10.1016/S0735-1097(03)00555-2 Stiebellehner, 2003, Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension, Chest, 123, 1293, 10.1378/chest.123.4.1293 Hoeper, 2003, Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids, Eur Respir J, 22, 330, 10.1183/09031936.03.00008003 Humbert, 2004, Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2, Eur Respir J, 24, 353, 10.1183/09031936.04.00028404 Petkov, 2003, Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension, J Clin Invest, 111, 1339, 10.1172/JCI17500 Cowan, 2000, Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease, J Clin Invest, 105, 21, 10.1172/JCI6539 Marcos, 2003, Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension, Am J Respir Crit Care Med, 168, 487, 10.1164/rccm.200210-1212OC Nagaya, 2004, Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension, Circulation, 109, 351, 10.1161/01.CIR.0000109493.05849.14